China’s nationwide registry reports surgical outcomes for 6,297 pancreatic cancer patients

Pancreatic cancer remains one of the most lethal malignancies in modern oncology, and surgical resection continues to offer the only realistic chance of long-term survival for the majority of patients diagnosed with the disease. Yet high-quality, nationwide data describing how pancreatic cancer surgery is actually performed and how patients actually fare after the operation have historically been scarce, particularly in countries with large and regionally diverse healthcare systems. A new annual data report from the China Pancreas Data Center, published in the Journal of Pancreatology, now provides one of the most comprehensive real-world pictures to date of pancreatic cancer surgery in China, drawing on 6,297 patients treated at 65 centers across the country between January 2020 and December 2021.

The China Pancreas Data Center, known as the CPDC, is a national multi-center online registration system that was initiated with the support of the Chinese Pancreatic Surgery Association, the Chinese Society of Surgery, and the Chinese Medical Association. Its purpose is straightforward: to collect standardized, prospectively entered data on pancreatic surgery from hospitals across China so that practice can be benchmarked, outcomes can be compared, and quality improvement initiatives can be grounded in evidence rather than anecdote. The newly published annual report represents a substantial step toward that goal, aggregating perioperative and survival outcomes for a patient volume that few single institutions anywhere in the world could hope to match.

The demographic and clinical profile of the 6,297 patients reflects the typical presentation of pancreatic cancer in a real-world setting. The median age at surgery was 64 years, and men outnumbered women with a male-to-female ratio of 1.2 to 1. Abdominal pain and jaundice emerged as the most common symptoms prompting diagnosis, a pattern consistent with the biology of the disease, which often remains silent until tumors grow large enough to cause obstruction or invade surrounding structures. Roughly 62.6 percent of patients presented with tumors located in the head or neck of the pancreas, the anatomical region where cancers most frequently compress the bile duct and where surgical resection, in the form of a pancreaticoduodenectomy, is among the most technically demanding operations in abdominal surgery.

One of the most closely watched metrics in modern pancreatic surgery is the adoption of minimally invasive techniques. Laparoscopic and robotic approaches have been promoted for their potential to reduce blood loss, shorten hospital stays, and speed recovery, but their role in cancer surgery depends on achieving oncological equivalence with open operations. In this national cohort, minimally invasive surgery was performed in 30.4 percent of cases, a figure that aligns with international benchmarks from high-volume pancreatic centers in Europe, North America, and East Asia. The conversion rate from minimally invasive to open surgery was 24.9 percent, a statistic that underscores the technical complexity of pancreatic resections and the importance of careful patient selection and surgeon experience in determining which approach is appropriate.

Systemic therapy played a prominent role in the treatment pathways captured by the registry. The predominant neoadjuvant and adjuvant chemotherapy regimen was nab-paclitaxel combined with gemcitabine, a doublet that has become a standard backbone for perioperative treatment of pancreatic cancer in guidelines around the world. The use of chemotherapy before and after surgery reflects a broader shift in the field, driven by clinical trials showing that multimodal treatment can improve survival even when the tumor is technically resectable. The CPDC data suggest that this paradigm has been widely integrated into Chinese surgical practice during the study period.

The safety metrics reported by the CPDC are the headline finding of the study and the numbers most likely to attract international attention. In-hospital mortality was just 0.6 percent, 30-day mortality was 1.2 percent, and 90-day mortality was 3.1 percent. For an operation historically associated with perioperative mortality rates in the double digits, these figures represent the cumulative result of decades of progress in surgical technique, perioperative care, centralization of complex surgery, and standardized postoperative management. Equally important for long-term prognosis, the one-, two-, and three-year overall survival rates reached 75.8 percent, 53.3 percent, and 42.0 percent, respectively. The authors state that these survival figures align with established benchmarks from international high-volume pancreatic centers, positioning China’s surgical outcomes for pancreatic cancer within the range of the best-performing systems worldwide.

Beyond the clinical numbers, the report offers a revealing portrait of how complex cancer surgery is organized across China’s vast and regionally uneven healthcare landscape. Nearly 45 percent of patients in the registry traveled across provincial borders to undergo their operations, a striking indicator of how far patients are willing to go to reach a surgeon or center they trust for one of the most complex operations in oncology. The authors attribute this pattern to regional disparities in medical resources rather than to patient preference alone. In advanced medical resource areas such as Beijing and Shanghai, over 99 percent of patients received their treatment locally, meaning that patients in those cities essentially never needed to leave home for surgery. The corollary is that patients in regions with fewer high-volume pancreatic surgery programs must often undertake long journeys to access equivalent care.

This geographic concentration of pancreatic cancer surgery in high-volume specialist centers carries both advantages and challenges. On the one hand, the centralization of complex procedures is widely recognized as a key driver of the low mortality and strong survival outcomes documented in the report, since outcomes in pancreatic surgery are closely tied to institutional volume and multidisciplinary expertise. On the other hand, the concentration creates access barriers for patients in less developed regions and places enormous demand on a limited number of centers. The authors emphasize the need to develop and roll out national-level benchmarks and standardized clinical protocols for pancreatic surgery across China, with the aim of raising the floor of care nationwide while preserving the strengths of the existing high-volume hubs.

The significance of the CPDC report extends beyond the borders of China. Real-world registry data of this scale are rare in pancreatic oncology, where much of the published evidence derives from single-center series, clinical trials with carefully selected populations, or national databases with variable completeness. A registry covering 65 centers and nearly 6,300 patients provides a granular view of who undergoes surgery, how the operations are performed, what perioperative therapies are delivered, and what outcomes result, all within a single standardized framework. For researchers and clinicians internationally, the report offers a benchmark against which other national systems can be compared, and for Chinese institutions it establishes a baseline for measuring the impact of future quality improvement efforts.

Pancreatic cancer accounts for a substantial and rising share of cancer deaths in China, and the demand for surgical treatment is expected to grow as the population ages and diagnostic capacity improves. The CPDC annual data report demonstrates that a coordinated national registry can capture the realities of surgical care at scale, from the adoption of minimally invasive techniques and perioperative chemotherapy to the regional patterns of patient travel and the hard endpoints of mortality and survival. As the registry continues to accumulate data in successive years, it is positioned to serve as an ongoing instrument for auditing performance, identifying gaps between centers, and guiding the standardization of pancreatic surgery across a healthcare system whose scale makes it unlike any other in the world. For the 6,297 patients whose outcomes form the backbone of this report, the findings confirm that pancreatic cancer surgery in China has reached a level of safety and effectiveness comparable to the leading international centers, while also making clear where the next phase of improvement must be directed.

Subject of Research: Real-world surgical outcomes for pancreatic cancer patients in China

Article Title: China reports real-world surgical outcomes for 6,297 pancreatic cancer patients

Article References: China reports real-world surgical outcomes for 6,297 pancreatic cancer patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, pancreatic surgery, China Pancreas Data Center, minimally invasive surgery, cancer registry, survival outcomes, Journal of Pancreatology, surgical oncology, China, reports, real-world, surgical